Skip to main content
Top
Published in: Pathology & Oncology Research 3/2016

01-07-2016 | Original Article

Prognostic Factors for Breast Cancer: an Immunomorphological Update

Authors: Luca Roncati, Giuseppe Barbolini, Federico Piacentini, Francesco Piscioli, Teresa Pusiol, Antonio Maiorana

Published in: Pathology & Oncology Research | Issue 3/2016

Login to get access

Abstract

The prognostic variability recorded within homogeneous groups of patients for anatomo-clinical disease stages has led to a more detailed biological characterization of breast cancer. Recently, the attention of the scientific community has focused on the role of tumor-infiltrating lymphocytes (TILs). Therefore, the need of an in-depth immunomorphological characterization of TILs has been emerged. The presence of TILs has been retrospectively investigated in 113 female cases of ductal carcinoma. An immunohistochemical investigation with CD3, CD4, CD8, CD20, CD56, granulysin, perforin-1, granzyme-B and TIA-1 was performed according to the standard procedures on all 17 cases with TILs evidence. TILs consisted of T and B lymphocytes: the prevalent population showed a T immunoprofile with a CD8-immunopositive killer subpopulation (Tk), close-linked to carcinomatous cells, and a CD4-immunopositive helper subpopulation (Th), inside the tumor. A time sequence (firstly T, then B) has been disclosed. Granulysin, perforin, granzyme-B and TIA-1 were expressed by Tk cells. The activated Tk cells secrete these mediators as a result of the binding to the tumor target cell, causing its lytic planned death. The cytotoxicity supported by Tk cells appears an important favorable prognostic factor. Therefore, a graduation system for TILs in breast cancer has been here proposed (absent, non-brisk, brisk).
Literature
1.
go back to reference World Health Organization. International Agency for Research on Cancer (2014) Breast cancer. Chapter 5.2. In: World Cancer Report 362–373 World Health Organization. International Agency for Research on Cancer (2014) Breast cancer. Chapter 5.2. In: World Cancer Report 362–373
2.
go back to reference Denoix PF (1946) Enquete permanent dans les centres antercancereux. Bull Inst Hyg 1:70 Denoix PF (1946) Enquete permanent dans les centres antercancereux. Bull Inst Hyg 1:70
3.
go back to reference Rathore AS, Kumar S, Konwar R, Srivastava AN, Makker A, Goel MM (2013) Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer 50:239–244CrossRefPubMed Rathore AS, Kumar S, Konwar R, Srivastava AN, Makker A, Goel MM (2013) Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer 50:239–244CrossRefPubMed
4.
go back to reference Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550CrossRefPubMed Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550CrossRefPubMed
5.
go back to reference Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 25:611–618CrossRefPubMedPubMedCentral Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 25:611–618CrossRefPubMedPubMedCentral
6.
go back to reference Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng WY, Ou Yang TH, et al. (2014) JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunol Res 2:301–306CrossRefPubMedPubMedCentral Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng WY, Ou Yang TH, et al. (2014) JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunol Res 2:301–306CrossRefPubMedPubMedCentral
7.
go back to reference Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713CrossRefPubMedPubMedCentral Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713CrossRefPubMedPubMedCentral
8.
go back to reference Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, et al. (2014) Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One 9:e95475CrossRefPubMedPubMedCentral Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, et al. (2014) Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One 9:e95475CrossRefPubMedPubMedCentral
9.
go back to reference Melichar B, Študentova H, Kalábová H, Vitásková D, Čermáková P, Hornychová H, et al. (2014) Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res 34:1115–1125PubMed Melichar B, Študentova H, Kalábová H, Vitásková D, Čermáková P, Hornychová H, et al. (2014) Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res 34:1115–1125PubMed
11.
go back to reference Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109:2796–2801CrossRefPubMedPubMedCentral Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109:2796–2801CrossRefPubMedPubMedCentral
12.
go back to reference Hussein MR, Hassan HI (2006) Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 59:972–977CrossRefPubMedPubMedCentral Hussein MR, Hassan HI (2006) Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 59:972–977CrossRefPubMedPubMedCentral
13.
go back to reference Tian Q, Taupin J, Elledge S, Robertson M, Anderson P (1995) Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 182:865–874CrossRefPubMed Tian Q, Taupin J, Elledge S, Robertson M, Anderson P (1995) Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 182:865–874CrossRefPubMed
14.
go back to reference Zhou J, Xu XZ, Hu YR, Hu AR, Zhu CL, Gao GS (2014) Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4+ T cells through the JAK2/STAT4/perforin pathway. Asian Pac J Cancer Prev 15:2439–2445CrossRefPubMed Zhou J, Xu XZ, Hu YR, Hu AR, Zhu CL, Gao GS (2014) Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4+ T cells through the JAK2/STAT4/perforin pathway. Asian Pac J Cancer Prev 15:2439–2445CrossRefPubMed
15.
go back to reference Roncati L, Barbolini G, Rivasi F (2010) Vascular endothelial growth factor/receptor systems expressed by basophils in vaginal angiomyofibroblastoma. Pathologica 102:351 Roncati L, Barbolini G, Rivasi F (2010) Vascular endothelial growth factor/receptor systems expressed by basophils in vaginal angiomyofibroblastoma. Pathologica 102:351
16.
go back to reference Busam KJ, Antonescu CR, Marghoob AA, Nehal KS, Sachs DL, Shia J, et al. (2001) Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. Am J Clin Pathol 115:856–860CrossRefPubMed Busam KJ, Antonescu CR, Marghoob AA, Nehal KS, Sachs DL, Shia J, et al. (2001) Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. Am J Clin Pathol 115:856–860CrossRefPubMed
17.
go back to reference Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S (2005) Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 446:10–14CrossRefPubMed Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S (2005) Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 446:10–14CrossRefPubMed
18.
go back to reference Manenti A, Roncati L, Sighinolfi P, Barbolini G (2014) Absence of immune response as a sign of tissue tolerance in small-cell lung cancer. Gene Cell Tissue 1:e20330CrossRef Manenti A, Roncati L, Sighinolfi P, Barbolini G (2014) Absence of immune response as a sign of tissue tolerance in small-cell lung cancer. Gene Cell Tissue 1:e20330CrossRef
Metadata
Title
Prognostic Factors for Breast Cancer: an Immunomorphological Update
Authors
Luca Roncati
Giuseppe Barbolini
Federico Piacentini
Francesco Piscioli
Teresa Pusiol
Antonio Maiorana
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-015-0024-7

Other articles of this Issue 3/2016

Pathology & Oncology Research 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine